Piemonte

Researchers are evaluating autologous tumor infiltrating lymphocytes (TIL) therapy called LN-145 in patients with metastatic non-small-cell lung cancer (NSCLC) without certain genetic mutations. This phase 2, open-label, multi-cohort, non-randomized, multicenter study aims to assess the treatment's effects in patients who have progressed after first-line therapies including immunotherapy and chemotherapy. LN-145 uses a special process to grow a patient's own immune cells to target cancer. The treatment involves removing a tumor sample from each patient, then growing the tumor infiltrating lymphocytes outside the body. Patients receive chemotherapy to reduce their immune cells before being given an infusion of their own expanded TIL cells (LN-145), followed by injections of IL-2 to support the immune response. The study includes patients with at least one resectable tumor for cell preparation and measurable tumors for evaluation. Participants will be monitored for tumor response and safety for up to 60 months. Assessments include imaging scans to measure tumor size and organ function tests. Researchers will track how well patients respond to the treatment and watch for side effects. Follow-up includes regular check-ups and evaluations over several years to understand the long-term effects of LN-145 therapy.